|
We asked 40 pharma leaders, which is your preferred social media tool for professional use?
| Twitter |
10% |
| LinkedIn |
64% |
| Facebook |
12% |
| Google+ |
10% |
| Other |
4% |
 |
|
|
|
|
|
|
|
3 July, 2012
|
| In this Issue |
Industry Calls for New Deal in Europe
EFPIA president Andrew Witty is hoping that the deepening European economic crisis will impel European leaders towards more courageous and radical solutions, writes Reflector. Read more... |
Europe Struggles with Clinical Trials Globalization
While the pharmaceutical industry has expanded its clinical trials internationally, this shift has been viewed with concern in some quarters.Some observers believe that there has been too much emphasis on economic benefits and that the ethical angles of globalization have not been fully explored, writes Nathan Jessop. More... |
Shire: Raising the Stakes in CNS
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Shire's Jeffrey Jonas is pushing a "search and develop" R&D model into new and sometimes uncomfortable territory. Ben Comer reports. More... |
Last Week's Historic US Healthcare Decision: What Now?
The US Supreme Court declaring the healthcare mandate can stand gives assurance that the rumbling, massive mechanism that the law has become over the last 2 ½ years will continue with its full development and deployment. In short, healthcare reform is fully on track for full implementation on January 1, 2014. Or is it? More...
|
|
|
|
|
